The success of Sildenafil initially fueled a boom for major pharmaceutical companies, nevertheless recent changes present a murky scenario for shareholders. Generic alternatives are eroding profits, and continued patent challenges add more complexity to the landscape. While certain companies could still gain from complementary products, the broader